Astera Labs (ALAB) Stock Surges 18% to All-Time High — And It Could Go Higher

TLDR

• ALAB hit a record closing high of $287.48 on Wednesday, up 18% on the day after a 13% gain Tuesday
• CEO Jitendra Mohan said Scorpio X fabric switches will be the company’s biggest product by end of 2026, with a ~$10B addressable market
• Evercore ISI raised its price target to $297, JP Morgan to $280; consensus is “Moderate Buy” with an average target of $233.75
• Q1 revenue came in at $308.36M, up 93.5% year-over-year, beating estimates; Q2 EPS guidance set at $0.68–$0.70
• The stock is up 73% in 2026 and has surged 699% since its IPO price of $36 in March 2024

---

Astera Labs (ALAB) stock hit $287.48 on Wednesday, closing at an all-time record high. That’s an 18% single-day gain, following a 13% jump on Tuesday. The stock is now up 73% in 2026 alone.

Astera Labs, Inc. Common Stock, ALAB

The two-day rally was driven by upbeat management commentary at a J.P. Morgan technology, media and communications conference, optimism ahead of Nvidia earnings, and a string of analyst price target upgrades.

CEO Jitendra Mohan took the stage at the conference on Tuesday. He said the Scorpio family of products would become Astera Labs’ largest revenue driver by the end of 2026.

Mohan put the total addressable market for the Scorpio X fabric switch product at around $10 billion. He also flagged optical networking as a new area Astera Labs is looking to enter.

“We are not shy about investing to make sure that we secure our place in the future,” Mohan said.

The company also touted its relationship with Nvidia, specifically its collaboration on the NVLink Fusion system for hyperscaler customers. Mohan described Astera Labs as “the Switzerland of connectivity” — positioned to work across all major AI platforms.

Analysts Raise Targets

Evercore ISI bumped its price target to $297 from $215, citing rising hyperscaler interest. JP Morgan raised its target to $280, also keeping an Overweight rating. Morgan Stanley moved its target to $240, up from $210, also Overweight.

TD Cowen raised its target to $225 from $140, though it kept a Hold rating. Rothschild & Co Redburn started coverage with a Neutral and a $153 target.

Fifteen analysts currently rate ALAB a Buy. Nine have a Hold. The average price target sits at $233.75 — below where the stock now trades.

Morgan Stanley’s Joseph Moore called Astera “one of the best growth rates in our coverage, with multiple product cycles and a very strong position in key AI technology.”

Q1 Results Beat Expectations

The recent rally has some earnings momentum behind it. Astera Labs reported Q1 EPS of $0.61, beating the $0.54 consensus. Revenue came in at $308.36 million, above the $292.19 million estimate.

That revenue figure represents a 93.5% increase from the same quarter last year. The company guided Q2 EPS to $0.68–$0.70, well above what Wall Street had expected.

Morgan Stanley credited Scorpio as “the primary driver of upside” following the Q1 print.

On the institutional side, Csenge Advisory Group opened a new position worth about $1.3 million in Q4. Several other funds also added to positions.

Insider activity tells a different story. Over the past 90 days, insiders sold 1.64 million shares worth approximately $288.7 million. General Counsel Philip Mazzara sold 14,076 shares on May 18 at $231.78. The sale was tied to tax obligations from equity vesting.

The stock carries a market cap of $49.28 billion and a P/E ratio of 194.24. Since its IPO at $36 in March 2024, ALAB has risen 699%.